Status:
COMPLETED
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Lead Sponsor:
Sanofi Pasteur, a Sanofi Company
Conditions:
Haemophilus Infections
Diphtheria
Eligibility:
All Genders
Up to 59 years
Brief Summary
To monitor the occurrence of invasive Hib disease over time and to determine product-specific rates of invasive Hib disease within the monitored population.
Detailed Description
The purpose of the study is to conduct surveillance for Hib disease. Prospective active population-based surveillance for invasive Hib disease, conducted by the Center for Disease Control and Prevent...
Eligibility Criteria
Inclusion
- Residence within the geographic scope of Active Bacterial Core surveillance (ABCs) during the period of surveillance
- Aged 0 through 59 months (prior to 5th birthday) on the day of inclusion for Hib disease surveillance and 2 through 23 months (prior to 2nd birthday) for Hib vaccine brand usage survey.
- 2009-2014 calendar years inclusive.
- For the Hib vaccine usage survey, agreement to complete the required survey.
Exclusion
- Not applicable.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
20830 Patients enrolled
Trial Details
Trial ID
NCT00855855
Start Date
February 1 2009
End Date
December 1 2014
Last Update
April 25 2022
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Albany, California, United States, 94706
2
Martinez, California, United States, 94553
3
San Francisco, California, United States, 94102
4
Applewood, Colorado, United States, 80401